Vol. 6 No. 6 (2026): June
Reimbursement Reviews

4% w/w Fluorouracil Sodium Cream (Tolak)

decorative image of the issue cover

Published June 22, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses 4% w/w fluorouracil sodium cream (Tolak), 40 mg/g, topical.
  • Indication: The topical treatment of actinic keratosis lesions of the face, ears, and/or scalp.